Langsjoen H, Langsjoen P, Langsjoen P, et al. Usefulness of coenzyme Q
10
in clinical cardiology: a long-term study.
Mol Aspects Med. 1994;15(suppl):S165–S175.
Langsjoen PH, Vadhanavikit S, Folkers K. Response of patients in classes III and IV of cardiomyopathy to therapy in a blind and crossover trial with coenzyme Q
10.
Proc Natl Acad Sci USA. 1985;82:4240–4244.
Poggesi L, Galanti G, Comeglio M, et al. Effect of coenzyme Q
10
on left ventricular function in patients with dilative cardiomyopathy.
Curr Ther Res. 1991;49:878–886.
Langsjoen PH, Langsjoen PH, Folkers K. A six-year clinical study of therapy of cardiomyopathy with coenzyme Q
10.
Int J Tissue React. 1990;12:169–171.
Langsjoen PH, Vadhanavikit S, Folkers K. Response of patients in classes III and IV of cardiomyopathy to therapy in a blind and crossover trial with coenzyme Q
10.
Proc Natl Acad Sci USA. 1985;82:4240–4244.
Permanetter B, Rossy W, Klein G, et al. Ubiquinone (coenzyme Q
10) in the long-term treatment of idiopathic dilated cardiomyopathy.
Eur Heart J. 1992;13:1528–1533.
Spigset O. Reduced effect of warfarin caused by ubidecarenone [letter].
Lancet.
1994;344:1372–1373.
Winter S, Jue K, Prochazka J, et al. The role of L-carnitine in pediatric cardiomyopathy.
J Child Neurol. 1995;10(suppl 2):S45–S51.
Pepine CJ. The therapeutic potential of carnitine in cardiovascular disorders.
Clin Ther. 1991;13:2–21.
Bertelli A, Ronca G. Carnitine and coenzyme Q
10: biochemical properties and functions, synergism and complementary action.
Int J Tissue React. 1990;12:183–186.
Please be aware that this information is provided to supplement the care provided by your physician. It is neither intended nor implied to be a substitute for professional medical advice. CALL YOUR HEALTHCARE PROVIDER IMMEDIATELY IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY. Always seek the advice of your physician or other qualified health provider prior to starting any new treatment or with any questions you may have regarding a medical condition.